Modern treatment of obesity and diabetes with GLP-1

Authors

  • Diego Silva Pacheco de Moraes Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud, Carrera de Medicina. Buenos Aires, Argentina Author
  • Marcelo Adrián Estrin Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud, Carrera de Medicina. Buenos Aires, Argentina Author

DOI:

https://doi.org/10.59471/ijhsc202553

Keywords:

Obesity, diabetes, GLP-1, efficacy, accessibility

Abstract

GLP-1 receptor agonists became established as an important tool in the treatment of obesity and type 2 diabetes. These drugs, initially developed to improve glycaemic control, demonstrated remarkable efficacy in reducing body weight. In Argentina, their approval offered new therapeutic possibilities, although their high cost limited access for many patients. In addition to promoting weight loss, these drugs improved the metabolic profile and reduced cardiovascular risk, although they also had adverse effects that required medical supervision. Their use required a comprehensive approach that included lifestyle changes and a complete medical evaluation.

References

Ma H, Lin YH, Dai LZ, et al. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023;13:e061807. doi:10.1136/bmjopen-2022-061807

Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251–61. doi:10.1007/s00125-022-05715-4. PMID: 35579691; PMCID: PMC9112245.

Li H, Yu G, Huang Q, Yang B, Nie J, Liu Y, et al. Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis. Biomed Pharmacother. 2024;171:116150. doi:10.1016/j.biopha.2024.116150. PMID: 38242040.

Guo X, Zhou Z, Lyu X, Xu H, Zhu H, Pan H, et al. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis. Horm Metab Res. 2022;54(7):458–71. doi:10.1055/a-1844-1176. PMID: 35512849.

Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22(1):41. doi:10.1186/s12933-023-01765-z. PMID: 36841762; PMCID: PMC9960425.

Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–13. doi:10.1001/jama.2021.1831. PMID: 33625476; PMCID: PMC7905697.

Cai W, Zhang R, Yao Y, Wu Q, Zhang J. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2024;12:1277113. doi:10.3389/fpubh.2024.1277113. PMID: 38356942; PMCID: PMC10864442.

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.

Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877–88. doi:10.1056/NEJMoa2302392. PMID: 37351564.

Silver HJ, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, et al. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. 2023;25(8):2340–50. doi:10.1111/dom.15113. PMID: 37188932; PMCID: PMC10544709.

Downloads

Published

2025-04-16

Issue

Section

Original

How to Cite

1.
Pacheco de Moraes DS, Estrin MA. Modern treatment of obesity and diabetes with GLP-1. Interamerican Journal of Health Sciences [Internet]. 2025 Apr. 16 [cited 2025 May 14];5:53. Available from: https://ijhsc.uai.edu.ar/index.php/ijhsc/article/view/53